Newbury Pharmaceuticals AB Statistics
Newbury Pharmaceuticals AB (NEWBRY) Stock Statistics & Valuation Metrics
Total Valuation
Newbury Pharmaceuticals AB has a market cap or net worth of SEK 61.40M. The enterprise value is SEK 36.14T.
- Market Cap
- SEK 61.40M
- Enterprise Value
- SEK 36.14T
Share Statistics
Newbury Pharmaceuticals AB has 30,397,888 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,397,888
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Newbury Pharmaceuticals AB’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -22.91%.
- Return on Equity (ROE)
- -0.30
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -22.91%
- Return on Capital Employed (ROCE)
- -0.23
- Revenue Per Employee
- 5.26M
- Profits Per Employee
- -2.20M
- Employee Count
- 7
- Asset Turnover
- 0.41
- Inventory Turnover
- 4.16
Valuation Ratios
The current PE Ratio of Newbury Pharmaceuticals AB is -2.73. Newbury Pharmaceuticals AB’s PEG ratio is -0.30.
- PE Ratio
- -2.73
- PS Ratio
- 1.44
- PB Ratio
- 0.00
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.30
Income Statement
In the last 12 months, Newbury Pharmaceuticals AB had revenue of 36.83M and earned -15.40M in profits. Earnings per share was -0.72.
- Revenue
- 36.83M
- Gross Profit
- 16.03M
- Operating Income
- -14.08M
- Pretax Income
- -15.41M
- Net Income
- -15.40M
- EBITDA
- -12.14M
- Earnings Per Share (EPS)
- -0.72
Cash Flow
In the last 12 months, operating cash flow was -11.63M and capital expenditures 0, giving a free cash flow of -11.63M billion.
- Operating Cash Flow
- -11.63M
- Free Cash Flow
- -11.63M
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Newbury Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -37.52%
Stock Price Statistics
- Beta
- 0.48
- 52-Week Price Change
- 2.85%
- 50-Day Moving Average
- 2.10
- 200-Day Moving Average
- 1.79
- Relative Strength Index (RSI)
- 57.99
- Average Volume (3m)
- 59.16K
Important Dates
Newbury Pharmaceuticals AB upcoming earnings date is Jan 20, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Jan 20, 2027
- Ex-Dividend Date
- ―
Financial Position
Newbury Pharmaceuticals AB as a current ratio of 1.49, with Debt / Equity ratio of 0.00%
- Current Ratio
- 1.49
- Quick Ratio
- 1.32
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.26
- Interest Coverage Ratio
- -9.20
Taxes
In the past 12 months, Newbury Pharmaceuticals AB has paid -4,000 in taxes.
- Income Tax
- -4,000
- Effective Tax Rate
- 0.00
Enterprise Valuation
Newbury Pharmaceuticals AB EV to EBITDA ratio is -3.34, with an EV/FCF ratio of 0.00.
- EV to Sales
- 1.43
- EV to EBITDA
- -3.34
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Newbury Pharmaceuticals AB has SEK 12.86M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 12.86M billion.
- Cash & Marketable Securities
- SEK 12.86M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 12.86M
- Net Cash Per Share
- SEK 0.42
- Tangible Book Value Per Share
- SEK 0.98
Margins
Gross margin is 24.83%, with operating margin of -48.40%, and net profit margin of -53.71%.
- Gross Margin
- 24.83%
- Operating Margin
- -48.40%
- Pretax Margin
- -53.69%
- Net Profit Margin
- -53.71%
- EBITDA Margin
- -42.89%
- EBIT Margin
- -48.40%
